Bottom line
Is FMED a good fund? The bottom line
FMED is an actively managed large blend ETF from Fidelity.
Annual fees run 0.5% — about $50 a year on every $10,000 invested, cheaper than 77% of large blend funds we track.
It returned +9.7% over one year, −0.2% a year over five years (as of Sep 30, 2026, per its prospectus).
With $41.0 million in net assets and 70 holdings, its largest position is Fidelity Revere Street Trust (10.3%) and the top 10 make up 39.4% of the portfolio.
What stands out
- Low cost: cheaper than 77% of large blend peers
What to watch
- 5-year return in the bottom quarter of its category
- Small fund ($41.0 million) — small funds are likelier to close
Updated Nov 19, 2026
What FMED invests in
Fidelity Disruptive Medicine ETF seeks long-term growth of capital.
"Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity's disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services. Disruptive medicine companies are companies that have or are developing innovative ways of doing business that may be disruptive in the development, design, manufacture, or distribution of products, processes, or services in the medical field. Companies within the disruptive medicine theme include but are not limited to those companies that, in…
From the fund's prospectus (filed Sep 24, 2026).
FMED performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FMED | +9.7% | −0.2% | — |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Sep 30, 2026
What FMED costs
On a $10,000 investment, FMED's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
FMED top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Fidelity Revere Street Trust | 10.27% |
| 2 | Ucb Sa | 4.73% |
| 3 | Lifestance Health Group Inc | 4.27% |
| 4 | Danaher Corp | 3.42% |
| 5 | 10x Genomics Inc | 3.11% |
| 6 | Intuitive Surgical Inc | 2.92% |
| 7 | Cogent Biosciences Inc | 2.85% |
| 8 | Alnylam Pharmaceuticals Inc | 2.79% |
| 9 | Argenx Se | 2.78% |
| 10 | Legend Biotech Corp | 2.29% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 39.4% of the fund. See all top 25 holdings and asset mix →